請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/15212完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 姜堯民 | |
| dc.contributor.author | Chia-Ying Lin | en |
| dc.contributor.author | 林佳穎 | zh_TW |
| dc.date.accessioned | 2021-06-07T17:28:34Z | - |
| dc.date.copyright | 2020-05-29 | |
| dc.date.issued | 2020 | |
| dc.date.submitted | 2020-05-17 | |
| dc.identifier.citation | 1. Amidu, M., & Abor, J. (2006). Determinants of dividend payout ratios in Ghana. The Journal of Risk Finance, 7(2), 136-145.
2. Bah, R., & Dumontier, P. (2001). R&D intensity and corporate financial policy: Some international evidence. Journal of Business Finance & Accounting, 28(5‐6), 671-692. 3. Beasley, M. S. (1996). An empirical analysis of the relation between the board of director composition and financial statement fraud. Accounting Review, 71(4), 443-465. 4. Beatty, R. P., & Zajac, E. J. (1994). Managerial incentives, monitoring, and risk bearing: A study of executive compensation, ownership, and board structure in initial public offerings. Administrative Science Quarterly, 39(2), 313-335. 5. Bhattacharya, S. (1979). Imperfect information, dividend policy, and “the bird in the hand” fallacy. Bell Journal of Economics, 10(1), 259-270. 6. Brickley, J. A., Coles, J. L., & Terry, R. L. (1994). Outside directors and the adoption of poison pills. Journal of Financial Economics, 35(3), 371-390. 7. Denis, D. J., & Osobov, I. (2008). Why do firms pay dividends? International evidence on the determinants of dividend policy. Journal of Financial Economics, 89(1), 62-82. 8. Fama, E. F., & French, K. R. (2001). Disappearing dividends: changing firm characteristics or lower propensity to pay?. Journal of Financial Economics, 60(1), 3-43. 9. Fama, E. F., & Jensen, M. C. (1983). Separation of ownership and control. The Journal of Law and Economics, 26(2), 301-325. 10. Fenn, G. W., & Liang, N. (2001). Corporate payout policy and managerial stock incentives. Journal of Financial Economics, 60(1), 45-72. 11. Harford, J., Mansi, S. A., & Maxwell, W. F. (2008). Corporate governance and firm cash holdings in the US. Journal of Financial Economics, 87(3), 535-555. 12. Jensen, M. C. (1986). Agency costs of free cash flow, corporate finance, and takeovers. The American Economic Review, 76(2), 323-329. 13. Jiraporn, P., Kim, J. C., & Kim, Y. S. (2011). Dividend payouts and corporate governance quality: An empirical investigation. Financial Review, 46(2), 251-279. 14. La Porta, R., Lopez‐de‐Silanes, F., Shleifer, A., & Vishny, R. W. (2000). Agency problems and dividend policies around the world. The Journal of Finance, 55(1), 1-33. 15. Lewellen, W., Loderer, C., & Martin, K. (1987). Executive compensation and executive incentive problems: An empirical analysis. Journal of Accounting and Economics, 9(3), 287-310. 16. Linck, J. S., Netter, J. M., & Yang, T. (2008). The determinants of board structure. Journal of Financial Economics, 87(2), 308-328. 17. Mitton, T. (2004). Corporate governance and dividend policy in emerging markets. Emerging Markets Review, 5(4), 409-426. 18. Myers, S. C., & Majluf, N. S. (1984). Corporate financing and investment decisions when firms have information that investors do not have (No. w1396). National Bureau of Economic Research. 19. Nagasawa, K., & Ito, A. (2016). R&D Investments and Dividend Policies: Reputation or Flexibility?. Available at SSRN 2870129. 20. Shleifer, A., & Vishny, R. W. (1986). Large shareholders and corporate control. Journal of Political Economy, 94(3, Part 1), 461-488. 21. Smith Jr, C. W., & Watts, R. L. (1992). The investment opportunity set and corporate financing, dividend, and compensation policies. Journal of Financial Economics, 32(3), 263-292. 22. Sougiannis, T. (1994). The accounting based valuation of corporate R&D. Accounting Review, 69(1), 44-68. 23. 林祝英, & 劉正義. (2003). 企業研發投資對融資, 股利政策與成長機會之影響-以電子資訊產業為例. 風險管理學報, 5(3), 319-339. 24. 丁琬芳. (2012). 我國生技領域產業研究發展投入與財務績效關係之研究-以製藥與醫療器材產業為例. 臺北大學國際財務金融碩士在職專班學位論文, 2012, 1-48. 25. 林穎芬, 黃麗津, & 陳思源. (2012). 經理人薪酬, 公司治理與現金股利政策. 中山管理評論, 20(4), 1213-1251. 26. 林穎芬, 洪晨桓, & 陳佳成. (2012). 臺灣上市公司董事薪酬影響因子之研究. 臺大管理論叢, 23(1), 175-207. 27. 巫文玲.(2016).產業技術評析－解盲事件後看新藥研發的成功.Retrieved November 24, 2019, from https://www.moea.gov.tw/MNS/doit/industrytech/IndustryTech.aspx?menu_id=13545&it_id=63 28. 智慧財產局. (2019). 2018智慧財產局年報. 取自https://www1.tipo.gov.tw/ct.asp?xItem=483190&ctNode=6950&mp=1. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/15212 | - |
| dc.description.abstract | 本研究探討台灣製藥業及非製藥生技業研發費用率與現金股利發放的關係，並探討高研發費用率又能發放較高現金股利之製藥公司特性。資料涵蓋2010～2018年的台灣製藥與非製藥生技公司，並採用每股現金股利做為應變數。結果顯示(1)高研發費用率的製藥公司增加研發費用率將減少現金股利發放，(2)較高的股東權益報酬率及較高的獨立董事佔比為能發放較高現金股利的高研發費用率製藥公司的特性。本研究發現獨立董事可以有效發揮公司治理的效果，提升公司的現金股利發放，避免管理者侵害股東的權益。 | zh_TW |
| dc.description.abstract | This paper examines the relationship between cash dividend payout and R&D expense ratio of pharmaceutical industry and non-pharmaceutical biotech industry in Taiwan during 2010 to 2018. This paper also discusses why some of the pharmaceutical companies with high R&D expense ratio could pay more cash dividends. The results are as follows. (1)There is negative relationship between cash dividend payout and R&D expense ratio for the high R&D expense ratio pharmaceutical companies. (2)Higher ROE and higher independent director ratio are the characteristics of high R&D expense ratio pharmaceutical companies that could pay more cash dividends. This paper finds that independent directors could fulfill the role in corporate governance, reduce conflicts of interest between managers and investors, and encourage firms to pay more cash dividends. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-07T17:28:34Z (GMT). No. of bitstreams: 1 ntu-109-R07723001-1.pdf: 1905430 bytes, checksum: f39121d1e0b9edeb31e936deceb71536 (MD5) Previous issue date: 2020 | en |
| dc.description.tableofcontents | 口試委員審定書 i
致謝 ii 中文摘要 iii Abstract iv 目錄 v 表目錄 vi 第一章 緒論 1 第二章 文獻回顧 3 第三章 研究方法與樣本 7 第四章 實證結果與分析 13 第五章 結論 17 參考文獻 18 表 一 台灣各產業研發費用率統計 21 表 二 製藥業及非製藥生技業公司清單 22 表 三 變數定義 23 表 四 製藥與非製藥生技業財務變數敘述統計量 25 表 五 製藥與非製藥生技業財務變數相關係數矩陣 26 表 六 製藥與非製藥生技業研發費用率與現金股利關聯 27 表 七 製藥與非製藥生技業研發費用率與現金股利關聯－營收分群 28 表 八 製藥與非製藥生技業研發費用率與現金股利關聯－研發費用率分群 29 表 九 高研發費用率製藥公司財務及公司治理變數敘述統計量 30 表 十 發放較高現金股利的高研發費用率製藥公司之特性 31 表 十一 製藥與非製藥生技業研發費用率與現金股利關聯(穩健性測試) 33 表 十二 製藥與非製藥生技業研發費用率與現金股利關聯－營收分群(穩健性測試) 34 表 十三 製藥與非製藥生技業研發費用率與現金股利關聯－研發費用率分群(穩健性測試) 35 表 十四 發放較高現金股利的高研發費用率製藥公司之特性(穩健性測試) 36 | |
| dc.language.iso | zh-TW | |
| dc.subject | 現金股利發放 | zh_TW |
| dc.subject | 公司治理 | zh_TW |
| dc.subject | 獲利能力 | zh_TW |
| dc.subject | 生技業 | zh_TW |
| dc.subject | 製藥業 | zh_TW |
| dc.subject | 研發費用率 | zh_TW |
| dc.subject | Pharmaceutical industry | en |
| dc.subject | R&D expense ratio | en |
| dc.subject | Cash dividend | en |
| dc.subject | Biotech industry | en |
| dc.subject | Profitability | en |
| dc.subject | Corporate governance | en |
| dc.title | 研發費用率與股利之關聯－以台灣製藥業及生技業為例 | zh_TW |
| dc.title | The Relation Between R&D Expense Ratio and Dividends – Evidence from Pharmaceutical and Biotech Industries in Taiwan | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 108-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 張邦茹,黃柏凱 | |
| dc.subject.keyword | 現金股利發放,研發費用率,製藥業,生技業,獲利能力,公司治理, | zh_TW |
| dc.subject.keyword | Cash dividend,R&D expense ratio,Pharmaceutical industry,Biotech industry,Profitability,Corporate governance, | en |
| dc.relation.page | 37 | |
| dc.identifier.doi | 10.6342/NTU202000837 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2020-05-18 | |
| dc.contributor.author-college | 管理學院 | zh_TW |
| dc.contributor.author-dept | 財務金融學研究所 | zh_TW |
| 顯示於系所單位： | 財務金融學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-109-1.pdf 未授權公開取用 | 1.86 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。